UK NICE reverses earlier negative opinion on Imbruvica (ibrutinib) in chronic lymphocytic leukaemia after price fall- Janssen
An earlier recommendation by the UK's NICE did not recommend Imbruvica (ibrutinib), from Janssen, for routine NHS use to treat chronic lymphocytic leukaemia. However, following a reduction in price, the independent appraisal committee were able to approve the drug as cost effective.
The NICE decision means ibrutinib can come off the Cancer Drugs Fund (CDF) and be routinely available. The draft guidance is now with consultees who have the opportunity to appeal against it. Once NICE issues final guidance on ibrutinib, the NHS must make it available within three months.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins